Orthofix PhysioStim's FDA Nod And CE Mark Boosts Prospects
Zacks Investment Research | Mar 07, 2018 10:30PM ET
As a major breakthrough in the field of PhysioStim, Orthofix International N.V. (NASDAQ:OFIX) has secured approvals from the U.S. FDA as well as the European CE Mark for its next-generation PhysioStim.
Per the company, the PhysioStim bone growth stimulators provide a non-surgical treatment option, particularly to patients with nonunion fracture beyond repair. In fact, such extremely critical conditions show no visible signs of healing.
The aforementioned Class III medical devices are built on Orthofix’s proprietary pulsed electromagnetic field (PEMF) technology platform. According to the company, PEMF signal creates a low-level electrical field at the fracture site, stimulating bone healing.
Orthofix sounds highly positive about PhysioStim, claiming the devices to have occupied a leading position as prescribed bone growth stimulators in the United States combined with spinal fusion stimulators. The company also stated that the PhysioStim devices will be accompanied by STIM onTrack, a new application for mobile devices. This app uses a first-to-market feature enabling physicians to remotely track and view patient adherence to their prescription.
Huge Market Prospect
We are certainly looking forward to this path-breaking achievement by the musculoskeletal healing device company in bone growth stimulation space, showing all indications to grow in leaps and bounds.
Going by a Grand View research report, the bone growth stimulator market size was valued at $1 billion in 2016 with more than 50 million Americans suffering arthritis. With arthritic problems rapidly rising due to aging and obesity factors, the patient population is likely to increasingly reach 78.4 million by 2040. Needless to add that this endemic arthritis is driving demand for bone growth stimulation products.
Taking global data into consideration, a Markets and Markets report states that the global bone growth stimulator market is estimated at $1.41 billion by 2022, witnessing a CAGR of 5.4%. The major growth propellers are growing patient preference for non-invasive and minimally invasive surgical treatments, increasing target patient population and procedural benefits offered by bone stimulation devices in bone fracture treatments.
In view of the above, we expect Orthofix to achieve a huge customer adoption rate for PhysioStim post the product launch in the United States and Europe.
Price Performance
Over the past three months, shares of Orthofix have outperformed the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.